Table 4 Sample’s characteristics according to the presence of no DM, prediabetes and DM, accessed by fasting glucose
Fasting glucose | P value | |||
|---|---|---|---|---|
<100 mg/dL | 100–126 mg/dL | ≥126 mg/dL | ||
n (%) | 169 (76.8) | 44 (20) | 7 (3.2) | |
Sex [n (%)] | 0.049 | |||
Male | 103 (60.9) | 23 (52.3) | 7 (100) | |
Female | 66 (39.1) | 21 (47.7) | 0 (0) | |
Age [years, [median (IR)] | 43 (15) | 51.5 (15) | 45 (14) | 0.027 |
Duration of HIV infection [years, [median (IR)] | 8 (6) | 8 (5.8) | 8 (6) | 0.782 |
cART [years, [median (IR)] | 6 (7) | 6 (5.8) | 8 (6) | 0.408 |
Clinical lipodystrophy [n (%)] | 0.082 | |||
Without CL | 76 (45) | 27 (61.4) | 2 (28.6) | |
With CL | 93 (55) | 17 (38.6) | 5 (71.4) | |
Body Composition [n (%)] | 0.004 | |||
No lipodystrophy | 26 (15.8) | 4 (9.8) | 1 (14.3) | |
Isolated central fat accumulation | 46 (27.9) | 22 (53.7) | 1 (14.3) | |
Lipoatrophy | 52 (31.5) | 6 (14.6) | 0 (0) | |
Mixed form of lipodystrophy | 41 (24.8) | 9 (22) | 5 (71.4) | |
BMI [(kg/m2), [median (IR)] | 24.4 (5.8) | 26.1 (5.5) | 26 (3.4) | 0.052 |
Waist circumference [cm, [median (IR)] | 88 (16.5) | 95 (13.5) | 95 (15) | 0.005 |
CD4 cell count [cells/mm3, [median (IR)] | 486 (344) | 525 (298) | 605 (382) | 0.643 |
HIV RNA (<50) [n (%)] | 151 (100) | 35 (100) | 6 (100) | |
Hepatitis C co-infection [n (%)] | 56 (33.5) | 6 (14.3) | 2 (28.6) | 0.034 |
CDC clinical categories [n (%)] | 0.398 | |||
A | 89 (52.7) | 27 (61.4) | 3 (42.9) | |
B | 3 (1.8) | 2 (4.5) | 0 (0) | |
C | 77 (45.6) | 15 (34.1) | 4 (57.1) | |
ART [n (%)] | ||||
IP | 96 (56.8) | 23 (52.3) | 4 (57.1) | 0.885 |
NNRTI | 79 (46.7) | 20 (45.5) | 3 (42.9) | 0.999 |
NRTI | 163 (96.4) | 41 (93.2) | 6 (85.7) | 0.157 |
HOMA-IR index [median (IR)] | 1.5 (1.3) | 3.2 (2.6) | 9.3 (6,8) | < 0.001 |
QUICKI index [median (IR)] | 0.4 (0.1) | 0.3 (0.04) | 0.3 (0.04) | < 0.001 |
Total cholesterol [mg/dL, median (IR)] | 220 (66) | 240.5 (86) | 234 (79) | 0.061 |
LDL- cholesterol [mg/dL, median (IR)] | 127 (67) | 149 (62) | 146 (74) | 0.136 |
HDL- cholesterol [mg/dL, median (IR)] | 47 (18) | 49 (22) | 41 (22) | 0.651 |
Triglycerides [mg/dL, median (IR)] | 189.5 (197.8) | 214.5 (207.8) | 184 (88) | 0.975 |
Statin use [n (%)] | 35 (20.7) | 8 (18.2) | 3 (42.9) | 0.312 |
Fibrate use [n (%)] | 50 (29.6) | 15 (34.1) | 0 (0) | 0.200 |